


Product Name : Alpelisib
Cat. No. : PC-20590
CAS No. : 1217486-61-7
Molecular Formula : C₁₉H₂₂F₃N₅O₂S
Molecular Weight : 441.47
Target : PI3K
Solubility : 10 mM in DMSO



CAS: 1217486-61-7

Biological Activity

Alpelisib (NVP-BYL719, BYL719) is a potent, selective, and orally active **PI3K α** inhibitor with IC₅₀ of 5 nM, >50-fold selectivity over p110 γ /p110 δ /p110 β .

Alpelisib (BYL719) potently inhibits PIK3CA somatic mutations (H1047R, E545K) with IC₅₀ of 4 nM.

Alpelisib (BYL719) potently inhibits Akt phosphorylation in cells transformed with PI3K α (IC₅₀=74 nM) and shows significant reduced inhibitory activity in PI3K β or PI3K δ isoforms transformed cells (>15-fold).

Alpelisib (BYL719) (0-50 μ M) inhibits the cell growth of osteosarcoma cell lines MG63, HOS, POS-1 and MOS-J in a dose-dependent manner.

Alpelisib (BYL719) potently suppresses proliferation and PI3K signaling in human breast cancer cells harboring PIK3CA(H1047R) in combination with lapatinib.

Alpelisib (BYL719) inhibits growth factor-independent KRASG12D BM colony formation and sensitizes cells to a low dose of the MEK inhibitor MEK162.

References

Furet P, et al. *Bioorg Med Chem Lett*. 2013 Jul 1;23(13):3741-8.

Gobin B, et al. *Int J Cancer*. 2015 Feb 15;136(4):784-96.

Fritsch C, et al. *Mol Cancer Ther*. 2014 May;13(5):1117-29.

Elkabets M, et al. *Sci Transl Med*. 2013 Jul 31;5(196):196ra99.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com